Last reviewed · How we verify
NCT03353610
The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
trial in Paroxysmal Supraventricular Tachycardia (PSVT) in 354 participants. Terminated before completion.
16 March 2020
Quick facts
| Lead sponsor | Milestone Pharmaceuticals Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 354 |
| Start date | 16 October 2017 |
| Primary completion | 16 March 2020 |
| Estimated completion | 16 March 2020 |
| Sites | 1 location across United States |
Conditions studied
- Paroxysmal Supraventricular Tachycardia (PSVT) — all drugs for Paroxysmal Supraventricular Tachycardia (PSVT) →
Sponsor
Milestone Pharmaceuticals Inc. — full company profile →
Who can join
Eligibility, any sex, with Paroxysmal Supraventricular Tachycardia (PSVT). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Paroxysmal supraventricular tachycardia (PSVT) is a sporadic, sudden, and recurring tachycardia that is caused by an altered electrical conductivity in the heart. It causes palpitations and a rapid heart rate, which may induce fear in the patient and negatively impact the patient's quality of life. Therefore, most patients experience not only physical symptoms of PSVT, but also dramatic psychological burdens. As PSVT drug development efforts advance, it has become increasingly important to document the impact of PSVT in a systematic way, in terms of the disease natural history and clinical characteristics of PSVT episodes, as well as the psychological impact of the condition as reported by patients over time. In order to meet the needs for ongoing, systematic data collection on PSVT, a multinational registry, The PSVT Place Registry (www.PSVTPlaceRegistry.com), is being implemented and will be initially comprised of data entered directly by patients. The long-term registry is designed with a participant-focused approach to enable continuity of data collection and minimization of impact from changes of participants' health care providers. The registry may be expanded at a later time to include physician-reported data. The information from the registry is planned to be a resource for participants with PSVT, their families and support networks, their doctors, and the research community to better understand PSVT-related symptoms and awareness, PSVT diagnoses, patient self-management, medical treatments for PSVT, and impact of PSVT on quality of life from the patient perspective.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03353610
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Milestone Pharmaceuticals Inc. trials
Trials by the same sponsor.
- NCT05763953 — The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) · Phase 2 · recruiting
- NCT04952610 — Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia · Phase 3 · enrolling by invitation
- NCT04467905 — ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 · Phase 2 · completed
- NCT04072835 — Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 · Phase 3 · completed
- NCT03635996 — Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycar · Phase 3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03353610 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Milestone Pharmaceuticals Inc.
- Last refreshed: 3 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03353610.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing